PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Inviter the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449A/PTO					are required to respond to a successive	Complete if Known		
						Application Number	New Application		
	INFC	RMATI	ON DI	SC	LOSURE	Filing Date	herewith		
					PLICANT	First Named Inventor	Maag, Hans et al.		
	0.,,					Art Unit	unassigned		
		(use as ma	ny sheets	as ne	ecessary)	Examiner Name	unassigned		
$\overline{}$	Sheet	Τ1		f ·	1	Attorney Docket Number	R0151B-REG		

U.S. PATENT DOCUMENTS						
Fisis	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials		Number - Kind Code ² (if known)	MM-DD-YYYY	Once boarners		
	A-1	US-6,214,829	04-10-2001	Feenstra, et al.		
	A-2	US-6,225,312	05-01-2001	Feenstra, et al.		
	A-3	US-5,424,313	06-13-1995	Hartog, et al.		

		FOREI	GN PATENT	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B-1	WO 02/34754, A2	05-02- 2002	Smithkline Beecham PLC (GB)	1 igui 00 / ppedi.	·
	B-2	WO 02/02529, A1	01-10- 2002	Knoll GmbH (DE)		
	B-3	WO 01/72725, A1	10-04- 2001	COR Therapeutics, Inc. (US)		
	B-4	WO 01/57003, A1	08-09- 2001	COR Therapeutics, Inc. (US)		
	B-5	WO 01/14330, A2	03-01- 2001	Solvay Pharmaceuticals B.V. (NL)		
	B-6	WO 97/36893, A1	10-09- 1997	Duphar International Research B.V. (NL)		

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner	1 1		T²		
	C-1	FEENSTRA, Rolf W. et al., "New 1-Aryl-4-(biarylmethylene)piperazines as Potential Atypical Antipsychotics Sharing Dopamine D ₂ —Receptor and Serotonin 5-HT _{1A} -Receptor Affinities," <i>Bioorganic & Medicinal Chemistry Letters</i> , (2001) pp. 2345-2349, No. 11, Pergamon			

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to

place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.